Soluble mesothelin-related protein - A blood test for mesothelioma

被引：77

作者：

Robinson, BWS

Creaney, J

Lake, R

Nowak, A

Musk, AW

de Klerk, N

Winzell, P

Hellstrom, KE

Hellstrom, I

机构：

[1] Univ Western Australia, Dept Med, Queen Elizabeth II Med Ctr, Nedlands, WA 6009, Australia

[2] Queen Elizabeth II Med Ctr, Western Australia Inst Med Res, Perth, WA, Australia

[3] Queen Elizabeth II Med Ctr, Sir Charles Gairdner Hosp, Dept Resp Med, Perth, WA, Australia

[4] UWA Ctr Child Hlth Res, Subiaco, WA, Australia

[5] Telethon Inst Child Hlth Res, Subiaco, WA, Australia

[6] Pacific NW Res Inst, Seattle, WA USA

来源：

LUNG CANCER | 2005年 / 49卷

关键词：

mesothelioma; SMRP; SMRP assay; serum markers;

D O I：

10.1016/j.lungcan.2005.03.020

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Identification of tumor marker for mesothelioma (MM) might prove useful in diagnosis as well as for monitoring tumor in response to therapy and for screening at-risk individuals. We tested the hypothesis that soluble mesothelin-related protein (SMRP), a mesothelin family member, in the serum would be such a marker. Our data show that determination of SMRP in serum is a marker of MM with a sensitivity of sensitivity 83% and specificity 95% in the first 48 MM patients tested. Changes in serum SMRP levels parallel clinical course/tumor size and SMRP is elevated in 75% of patients at diagnosis. SMRP should also be useful for monitoring disease progression, and importantly, may prove useful for screening asbestos-exposed individuals for early MM. Crown Copyright (c) 2005 Published by Elsevier Ireland Ltd. All rights reserved.

引用

页码：S109 / S111

页数：3

共 23 条

[1] MALIGNANT MESOTHELIOMA - PROGNOSTIC VARIABLES IN A REGISTRY OF 180 PATIENTS, THE DANA-FARBER-CANCER-INSTITUTE AND BRIGHAM-AND-WOMENS-HOSPITAL EXPERIENCE OVER 2 DECADES, 1965-1985 [J].